Investors focused on the Medical space have likely heard of Avinger (AVGR - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.
Avinger is one of 844 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. AVGR is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for AVGR's full-year earnings has moved 58.76% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that AVGR has returned about 56.67% since the start of the calendar year. At the same time, Medical stocks have gained an average of 3.57%. This shows that Avinger is outperforming its peers so far this year.
Looking more specifically, AVGR belongs to the Medical - Instruments industry, which includes 93 individual stocks and currently sits at #105 in the Zacks Industry Rank. Stocks in this group have gained about 6.55% so far this year, so AVGR is performing better this group in terms of year-to-date returns.
AVGR will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Investors focused on the Medical space have likely heard of Avinger (AVGR - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? Let's take a closer look at the stock's year-to-date performance to find out.
Avinger is one of 844 companies in the Medical group. The Medical group currently sits at #2 within the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. AVGR is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for AVGR's full-year earnings has moved 58.76% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Our latest available data shows that AVGR has returned about 56.67% since the start of the calendar year. At the same time, Medical stocks have gained an average of 3.57%. This shows that Avinger is outperforming its peers so far this year.
Looking more specifically, AVGR belongs to the Medical - Instruments industry, which includes 93 individual stocks and currently sits at #105 in the Zacks Industry Rank. Stocks in this group have gained about 6.55% so far this year, so AVGR is performing better this group in terms of year-to-date returns.
AVGR will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on AVGR - FREE